Abstract:Aim: This study aims to identify novel steroidal 5-alpha reductase (5AR) inhibitors using computational approaches. Objectives: The objective of this study is to exploit the steroidal nuclei for possible modifications by creating a library of 17-oximino-5-androsten-3-carboxamide derivatives and identify potent 5AR inhibitors based on docking and pharmacokinetic parameters. Background: Benign prostatic hyperplasia (BPH) is a condition of aged men that is characterized by lower urinary tract symptoms. Excessive production of dihydrotestosterone (DHT) from testosterone has been found to play a major role in its pathophysiology. Studies targeting the 5AR enzyme have so far resulted in the development of two clinically approved 5AR inhibitors. Methods: Atom-based three-dimensional-quantitative structure-activity relationship (3D-QSAR) models have been developed using a selected series of steroidal derivatives as 5AR inhibitors to elucidate the structural properties required for 5AR inhibitory activities. Further in‒silico studies (molecular docking and pharmacokinetic properties like adsorption, distribution, metabolism, and excretion) of 17- oximino-5-androsten-3-carboxamide derivatives have also been carried out to identify the binding orientation and protein-ligand interactions responsible for the exhibited activity and drug like properties. Results: The best 3D-QSAR model was generated using Partial Least Square method with an excellent correlation coefficient (R2, training set) of 0.882, standard deviation (SD) of 0.09, and a predicted coefficient (Q2, test set) of 0.814. Docking analysis indicated that the designed series of compounds have comparable binding affinity from -8.961 to -8.017 to the protein and suggested that hydrophobic and electrostatic moieties can have a key role in the inhibition mechanism. Conclusion: 3D-QSAR, molecular docking and pharmacokinetic studies indicated that 17-oximino-5- androsten-3-carboxamide derivatives could be studied further to provide a new strategy for the treatment of BPH.

UV-spectrophotometric Screening of 5α-Reductase Inhibitors in vitro

Progress in the Study of 5Α-Reductases Used As A Target in Natural Medicine Screening

UV-spectrophotometric screening of 5α-reductase inhibitors for benign prostatic hyperplasia treatment

Screen Steroid 5 Alpha- Reductase Inhibitors in Vitro by High Performance Liquid Chromatography

[Natural 5Α-Reductase Inhibitors in Treatment of Benign Prostatic Hyperplasia].

Screening for Aromatase Ligands in the Extract of Broussonetia Papyrifera Using High Performance Liquid Chromatography and ESI-mass Spectrometry

The Screening of 5α-Reductase Inhibitor from Botanic Substance for Anti-Ances

Fully Automated Chip-Based Nanoelectrospray Ionization-Mass Spectrometry As an Effective Tool for Rapid and High-Throughput Screening of 5Α-Reductase Inhibitors

Rapid Screening of Lipase Inhibitors from Fructus Aurantii Using Lipase-Immobilized Magnetic Beads Coupled with High-Performance Liquid Chromatography-Mass Spectrometry

Isolation and Identification of Active Compounds on Benign Prostate Hyperplasia from Oiltea camellia Extract

3D-QSAR, Molecular Docking and Pharmacokinetic Studies: In-Silico Approach to Search Novel Inhibitors of 5-Alpha Reductase for Treatment of Benign Prostatic Hyperplasia

Design, Synthesis and Biological Evaluation of Novel Androst-3,5-diene-3-carboxylic Acid Derivatives As Inhibitors of 5Α-Reductase Type 1 and 2

Active Constituents of Urtica Fissa in Inhibition of Benign Prostatic Hyperplasia

Analysis on the Activity of 5Α-Reductase Using High Performance Liquid Chromatography

A Review on Steroidal 5 alpha-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia

Recent Advances in Research on Nonsteroidal 5α-Reductase Inhibitors

Inhibitory Effect of Neferine and Isoliensinine on 5α-Reductase

In vitro inhibition of 5-α reductase and in vivo suppression of benign prostatic hyperplasia by Physalis angulata ethyl acetate extract

New 5alpha-reductase inhibitors: in vitro and in vivo effects

UPLC-MS/MS-Based Target Screening of 90 Phosphodiesterase Type 5 Inhibitors in 5 Dietary Supplements

5α-reductase inhibitor in the treatment of benign prostatic hyperplasia